EW-7197 CAS 1352608-82-2

Name

EW-7197

Synonyms

N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazole-2-methanamine;NOV-1301;TEW-7197;N-[[4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]methyl]-2-fluoroaniline

Molecular Formula

C22H18FN7

Molecular Weight

399.42

CAS Number (Or Watson Number for Non-CAS Products)

1352608-82-2

EINECS

Specs/Standards

98%min

Use

EW-7197 is a highly potent, selective, and orally bioavailable TGF-¦Â receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively. target: ALK4/ALK5 IC 50: 13 nM for TGF-¦Â receptor ALK4, 11 nM for TGF-¦Â receptor ALK5. In vitro: EW-7197 inhibits TGF¦Â-induced Smad2 or Smad3 phosphorylation and the epithelial-to-mesenchymal transition (EMT) in TGF¦Â-treated breast cancer cells. In addition, EW-7197 also abrogates TGF¦Â1-induced tumor cell migration and invasion in breast cells. EW-7197 inhibited Smad/TGF¦Â signaling, cell migration, invasion, and lung metastasis in mouse mammary tumor virus. In vivo: EW-7197 inhibition downregulates Smad4 in melanoma-bearing mice. EW-7197 induces ubiquitin-mediated degradation of Smad4 in melanoma-bearing mice. In a mouse B16 melanoma model, EW-7197 (2.5 mg/kg daily p.o.) suppresses the progression of melanoma with enhanced cytotoxic T-lymphocyte (CTL) responses. EW-7197 dissolved in artificial gastric fluid formulation (vehicle; ddH2O 900 ml, conc. HCl 7 ml, NaCl 2.0 g, pepsin 3.2 g) was given orally by feeding needle to mice from 4 days after inoculation.

Sales Link

This product is exclusively sold through our sales company Watson International Ltd and please refer to the link below for inquiries
http://watson-int.com/EW-7197-cas-1352608-82-2/